Jun 26, 2025 · 29m · tbpn
Andrew Huberman on the Uncertain Future of Science
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
Neurobiologist Andrew Huberman examines the looming threats of proposed NIH budget cuts and institutional distrust while outlining structural reforms, modern funding models, and emerging therapeutic breakthroughs needed to revitalize scientific innovation.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →
The hosts as informed peer 2.6 Guest teaching 5.2 Guest disagreement 2.0 The hosts pushing back 0.0
speaking balance: gold is the hosts, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 12:40 Calling out gray market biohacking and grant cowardice
Huberman forcefully dismisses the conservative grant submission culture and calls the unregulated gym testing of unstudied peptides outright bullshit.
Hardest push from the hosts ▶ 13:13 Prompting on commercial incentives and peptide patentabilityThe host redirects the focus to systemic commercial dynamics, querying whether the lack of peptide research is strictly driven by patentability constraints.
Biggest teaching moment ▶ 21:00 Explaining the deletion test and peer review biasHuberman educates the audience on internal NIH study sections, explaining why close peer review fails and how the deletion test should audit taxpayer-funded research.
The host holds their own ▶ 13:20 Citing pharmaceutical patent modification requirementsThe host displays his knowledge of pharmaceutical industry mechanics by asking whether drug developers must synthesize specific molecular variants to gain patent protection.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The hosts as informed peer | Guest teaching | Guest disagreement | The hosts pushing back | Why |
|---|---|---|---|---|---|---|
| Congressional NIH Budget Cuts and the Foundation of Basic Research | 4 | 5 | 1 | 0 | The host asks about NIH budget cuts and clarifies that basic research covers non-commercial work. Huberman explains the fundamental structure and historical importance of NIH basic funding in detail. | |
| Public Backlash, Institutional Distrust, and Pandemic Missteps | 1 | 6 | 3 | 0 | Huberman delivers an uninterrupted monologue detailing public dissatisfaction, pandemic communication failures, and scientific fraud revelations. The hosts listen passively. | |
| The Controversy Over Indirect Costs and University Funding | 3 | 6 | 2 | 0 | Huberman explains indirect cost (IDC) controversies and university endowments before addressing what frontier research needs protection. The hosts ask clarifying and open-ended framing questions. | |
| Balancing Lifestyle Interventions with Mechanistic Science and Systemic Flaws | 4 | 5 | 3 | 0 | Huberman highlights systemic grant funding flaws where labs only submit already-completed research, calling out gray market biohacking. The host offers brief, informed context on patenting limits. | |
| Therapeutic Peptides, Novel Sleep Drugs, and Stem Cell Hazards | 4 | 6 | 2 | 0 | The host asks whether drug companies must modify naturally occurring peptides to patent them. Huberman provides extensive clinical examples, novel sleep mechanisms, and severe stem cell hazards. | |
| Responsible Science Communication, Psychedelic Trials, and Medication Risks | 3 | 6 | 2 | 0 | The host asks about podcaster responsibility in health communication. Huberman details trial data on psilocybin, MDMA, ibogaine, and severe adverse effects from common pharmaceuticals like finasteride. | |
| The Deletion Test and Structuring Accountability in Research Grants | 1 | 7 | 3 | 0 | Huberman outlines his proposal for the deletion test and critiques standard peer review dynamics when evaluating grant significance. The hosts do not interject. | |
| Transitioning from Investigator-Centric Labs to Collaborative Mission Incubators | 2 | 6 | 2 | 0 | The host asks how to ensure strong scientific progression, and Huberman advocates replacing investigator-centric labs with mission-focused, tech-incubator style research hubs. | |
| Restoring Public Trust and Harnessing the Energy of Young Scientists | 3 | 5 | 2 | 0 | The host raises concerns about eroded public trust discouraging young people from entering science. Huberman agrees and elaborates on how to harness youth energy without bureaucratic clunkiness. | |
| Final Appreciations and Podcast Conclusion | 1 | 0 | 0 | 0 | Huberman praises the hosts' show and media distribution style, ending the interview on a friendly and appreciative note. |
Statements from this episode (21)
Huberman: Congress is considering a 40% cut to NIH research budget
“There is an upcoming vote in Congress in September, I believe, and it's on the table to cut the overall budget for research for NIH by 40%, four to zero.”
Huberman: NIH funds most US basic research and clinical trials
“Most of the basic research and clinical trials that are run in the United States are funded by the NIH.”
Huberman: Majority of Nobel Prizes in medicine originated from NIH funding
“The majority of Nobel Prizes has, in physiology and medicine, ah, and chemistry and related fields have come from work that was Either initially seeded by or certainly supported by the NIH.”
Huberman: Administration potentially restructuring NIH from 20+ institutes to eight
“The current administration seems to be taking a more like, they're gonna revise the way that NIH is structured potentially, 20 plus institutes down to eight, so all of it looks like downsizing.”
Huberman: Trump administration proposed capping university indirect costs at 15%
“Earlier this year, the Trump administration said, We're cutting that to 15% across the board for all universities”
Huberman: Slashing indirect research costs will disproportionately hurt unendowed public universities
“I just personally, it's my view, this is my personal view, is that a severe cut to the indirects, while on the face of it might sound good, that's going to disproportionately Hurt the public schools without large endowments, okay, because they don't have money…”
Huberman: GLP-1 proved people become fat because they eat too much
“It also, by the way, shut down the debate as to why people are fat. It's because they eat too much.”
Huberman: NIH grants often fund already-completed research rather than bold science
“Much of the work that's funded by NIH Here's the dirty secret is already completed because they tend to fund things that are very certain to be completed. And so people put forward grants based on work and preliminary data showing I can do this and it's alread…”
Huberman: Peptides should not be relegated to gray-market gym testing
“It's my opinion that every single peptide, not just GLP-I, every single peptide shouldn't be getting tested in the gray market of, like, gyms and, like, biohacking. That's, frankly, that's bullshit.”
Huberman: BPC-157 has solid animal studies but zero human clinical trials
“Like BPC- one five seven, right? You hear about that all the time is, will it accelerate healing? You know, the animal studies are solid. There's no human studies.”
Huberman: DORA sleep drugs preserve sleep architecture but cost $325 monthly
“The Doras have been released, right? They maintain the architecture of sleep pretty well compared to other sleep drugs like Ambien, etc. Here's the issue. They're about 325 dollars a month.”
Huberman: Stem cells are not yet ready for clinical use
“No, they're not ready for clinical use yet, and the United States has been very careful about things like this”
Huberman: Data shows microdosing psilocybin lacks major effects on depression or PTSD
“The data on microdosing psilocybin Are basically clear that it's not known to have any major effect on major depression or some of the other things that psilocybin is being tested for clinically including major depression, PTSD, et cetera.”
Huberman: MDMA will ultimately receive FDA approval for PTSD
“So I think ultimately it will be approved.”
Huberman: Properly dosed MDMA yields 60% to 70% PTSD remission rates
“The remission rates on PTSD, by the way, from Properly dosed and spaced MDMA is remarkable. Up to somewhere between 60 and 70% remission rates on PTSD.”
Huberman: Hair loss drugs finasteride and dutasteride can cause permanent sexual dysfunction
“There's this whole thing about people taking finasteride and dutasteride men to keep their hair and getting permanent sexual dysfunction, right? Permanent sexual dysfunction. Some of them killing themselves as a consequence of this.”
Huberman: Funded research grants often fail the critical laboratory deletion test
“I sat on study section for a long time, and I can tell you there were clusters of grants that didn't solve what we call, what good labs call, the deletion test. If this laboratory didn't exist, would it change the direction of science? You have to pass the del…”
Huberman: Using Close Peer Juries for Grant Evaluation Is Flawed
“The idea that a jury of close peers are going to decide the deletion test, and if you pass, that's flawed in my opinion, because the end culture, we don't have time for this, but the end culture of science is, you know, people aren't like helping each other ou…”
Huberman: U.S. Academic Science Should Replace PI Labs With Mission-Driven Incubators
“I think the independent investigator model of science in this country, where it's the Huberman lab, or it's the whatever lab named after the PI, I think that's a flawed model. This is gonna really upset some people. There should be labs named after a particula…”
Huberman: Schizophrenia Lacks Strong Research Lobby Despite Affecting 1% of Population
“So where, the reason we don't have a cure for schizophrenia, even though it's one percent of the world's population, is, sadly, it tends to run in families. There's not a strong lobby for research on schizophrenia. The director of NIMH told me that, former dir…”
Huberman: Optimal Science Funding Gives Young Researchers Autonomy to Iterate Quickly
“You get money, you give it to young people, and you get the fuck out of their way and let them try. And then when they don't work, you guide them and you say, listen, like you're wasting your time, move on. And eventually you get hits. And then if you compile …”